PT  - JOURNAL ARTICLE
AU  - M S Luck
AU  - P Bass
TI  - Effect of epidermal growth factor on experimental colitis in the rat.
DP  - 1993 Feb 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 984--990
VI  - 264
IP  - 2
4099  - http://jpet.aspetjournals.org/content/264/2/984.short
4100  - http://jpet.aspetjournals.org/content/264/2/984.full
SO  - J Pharmacol Exp Ther1993 Feb 01; 264
AB  - The effect of epidermal growth factor on the rate of healing was examined in a rat model of colitis. Ulceration and inflammation of the distal colon were induced by a single intracolonic administration of 0.25 ml of 30% ethanol containing 30 mg of trinitrobenzenesulfonic acid. Epidermal growth factor was delivered intracolonically via the rectum or s.c. for 7 days after induction of colitis. Repeated s.c. injections of epidermal growth factor (25 and 100 micrograms/kg/12 hr) or continuous s.c. delivery with Alzet osmotic pumps (50 and 200 micrograms/kg/24 hr) significantly reduced colonic ulceration and inflammation. Epidermal growth factor significantly reduced myeloperoxidase activity in colonic tissue and there was restitution of the glandular mucosa after epidermal growth factor treatment. In contrast, daily intracolonic treatment with epidermal growth factor (25, 100 and 200 micrograms/kg/24 hr) did not significantly reduce the colonic damage. However, intracolonic delivery of 5-aminosalicylic acid (100 and 200 mg/kg/24 hr) dose-dependently reduced the colonic damage as assessed macroscopically and histologically. We conclude that systemic and not intracolonic administration of epidermal growth factor can accelerate healing of colonic ulceration and is effective in reducing inflammation in this model of colitis.